亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Durvalumab and consolidation SBRT following chemoradiation for stage III non-small cell lung cancer: A single institution pilot study.

作者
Paul P. Koffer,Hetal Mistry,Jaroslaw T. Hepel,Thomas A. DiPetrillo,Roxanne Wood,Vallerie Rosati,Ariel E. Birnbaum,Christopher G. Azzoli,Humera Khurshid,Hina Khan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): e20085-e20085
标识
DOI:10.1200/jco.2024.42.16_suppl.e20085
摘要

e20085 Background: Definitive chemoradiation (CRT) followed by consolidative immunotherapy with durvalumab (IO) demonstrated survival benefit and is now standard of care for Stage III Non-small Cell Lung Cancer (NSCLC). However, local-regional control (LRC) remains a concern with intrathoracic progression representing the most common site of failure. Adding stereotactic body radiotherapy (SBRT) boost may enhance the immunogenicity and antigenicity of tumor cells by regulating cell surface receptors and augmenting T-lymphocyte infiltration into tumor. SBRT boost also allows escalated dose to the primary tumor while minimizing dose to critical structures. Methods: Patients with Stage III NSCLC planned for definitive concurrent CRT with 1 year of consolidative IO were prospectively enrolled on a single institutional pilot trial. IO started 6-8 weeks after completion of CRT. SBRT was delivered between cycle 1 and 2 of IO to the residual, primary tumor (20 Gy in 2 fractions for peripheral, 19.5 Gy in 3 fractions for central tumors). Residual tumors needed to be < 120 cc. Lymph nodes were not boosted. Primary endpoints were grade (gr) ≥3 toxicities (CTCAE V4.03) and progression free survival (PFS). Secondary endpoints were Overall Survival (OS), LRC, and distant metastasis (DM). A sample size of 25 patients was proposed to determine safety and efficacy. Results: Accrual was slower than anticipated, and the study closed with 11 patients enrolled over 54 months. Slow accrual was due to a low rate of eligibility based on post CRT clinical status and SBRT target limitations. 1 patient withdrew consent before receiving treatment leaving 10 evaluable patients. Median age was 73 years and median CRT dose was 60 Gy (range 60-66 Gy). 6/10 of patient were adenocarcinoma. 5/10 pts had central tumor location. Median follow-up for evaluable patients is 2.2 years. OS was 90%, 70%, and 70% at 1-year, 2-years, and 3 years, respectively. PFS was 90%, 47%, and 47% at 1 year, 2 years, and 3 years, respectively. LRC was 100%, 83%, and 63% at 1 year, 2 years, and 3 years, respectively. Rates of DM were 0%, 12%, and 34% at 1 year, 2 years, and 3 years, respectively. 1 patient developed gr 3 pneumonitis requiring discontinuation of IO. 1 additional patient developed gr 2 pneumonitis requiring a brief pause in IO therapy and resumed IO without any further complications. One patient developed gr 5 myocarditis 29 days after the first dose of IO and 18 days after SBRT, on investigation deemed to be myocarditis secondary to IO. There was no other gr 3 toxicity attributable to IO or SBRT. Conclusions: The addition of SBRT to consolidative IO in stage III NSCLC patients treated with CRT was feasible. The single gr 5 toxicity was attributed to IO. SBRT boost demonstrated encouraging efficacy and manageable toxicity and merits further study. Our data adds to the growing evidence of harnessing tumor immunogenicity in enhancing IO responses. Clinical trial information: NCT03589547 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
隐形曼青的应助被amiee采纳,获得10
4秒前
领导范儿的应助被佳佳采纳,获得10
11秒前
16秒前
动听阑悦完成签到 ,获得积分10
17秒前
淡淡的志泽完成签到,获得积分10
23秒前
23秒前
39秒前
Peiqi的应助被1874采纳,获得100
43秒前
farhad发布了新的文献求助10
44秒前
52秒前
petrichor发布了新的文献求助10
56秒前
syvshc的应助被宝石采纳,获得10
56秒前
大胆蛟凤完成签到,获得积分10
59秒前
1分钟前
may发布了新的文献求助10
1分钟前
1分钟前
五十二赫兹完成签到 ,获得积分10
1分钟前
2分钟前
大模型的应助被科研通管家采纳,获得10
2分钟前
2分钟前
高速公鹿发布了新的文献求助10
2分钟前
舒适刺猬完成签到 ,获得积分10
2分钟前
魏魏完成签到 ,获得积分10
2分钟前
旭旭完成签到,获得积分10
2分钟前
对白完成签到,获得积分10
2分钟前
ysh完成签到,获得积分10
3分钟前
林夕完成签到,获得积分10
3分钟前
3分钟前
和风完成签到 ,获得积分10
3分钟前
3分钟前
amiee发布了新的文献求助10
3分钟前
3分钟前
1874发布了新的文献求助30
3分钟前
3分钟前
穿肠酒发布了新的文献求助10
3分钟前
3分钟前
4分钟前
科研通AI6.3的应助被半亩月光采纳,获得10
4分钟前
魔幻初丹完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190117
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852170
捐赠科研通 7788359
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559994
邀请新用户注册赠送积分活动 2482862